Could ICER Outreach To US FDA Lead To Better Cost Effectiveness Analyses?
Executive Summary
To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.